NASDAQ:ATRA Atara Biotherapeutics Q1 2026 Earnings Report $10.46 +0.60 (+6.09%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Atara Biotherapeutics EPS ResultsActual EPS-$0.29Consensus EPS -$0.33Beat/MissBeat by +$0.04One Year Ago EPSN/AAtara Biotherapeutics Revenue ResultsActual Revenue$0.52 millionExpected Revenue$2.90 millionBeat/MissMissed by -$2.38 millionYoY Revenue GrowthN/AAtara Biotherapeutics Announcement DetailsQuarterQ1 2026Date5/12/2026TimeBefore Market OpensConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsAtara Biotherapeutics' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Atara Biotherapeutics Earnings HeadlinesQuetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic LeukemiaJune 11 at 6:52 AM | globenewswire.comAtara Biotherapeutics Inc (ATRA)May 31, 2026 | investing.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 11 at 1:00 AM | Behind the Markets (Ad)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRAMay 26, 2026 | prnewswire.comATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their RightsMay 22, 2026 | businesswire.comAtara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 22, 2026 | prnewswire.comSee More Atara Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email. Email Address About Atara BiotherapeuticsAtara Biotherapeutics (NASDAQ:ATRA) is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders. The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers. In addition, Atara is advancing multiple earlier-stage programs, including ATA188 for progressive multiple sclerosis and ATA227 for autoimmune indications, each harnessing the company’s expertise in antigen-specific T-cell biology. Atara’s pipeline is supported by manufacturing and process development capabilities aimed at delivering scalable, cryopreserved cell therapies for global distribution. Founded in 2012, Atara Biotherapeutics has built a diversified clinical portfolio and established collaborations to advance its therapies across North America, Europe and Asia. The company’s leadership team combines expertise in cell therapy development, regulatory affairs and commercial strategy, guided by President and Chief Executive Officer Pascal Touchon. Through ongoing clinical studies and strategic partnerships, Atara aims to address unmet medical needs in oncology and autoimmune disease with its off-the-shelf T-cell products.View Atara Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Spotify's "North Star" Outlook Was Music to Investors EarsCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market ThinksCasey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance AlignThe “Duck Stock” Keeps Quietly Making Money for ShareholdersEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthAs Shares Fall, Analyst Are Boosting their Broadcom Price Targets Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
